Abnormal Angiogenesis in Hereditary Haemorrhagic Telangiectasia: VEGF-, FGFR- and PI3K/AKT/mTOR-Targeted Therapies and IMiDs—A Narrative Review
Rare Diseases and Therapeutics · 18.11.2026 · 1 (1) · 2
DOI: 10.3390/rdt1010002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rare Diseases and Therapeutics, online erschienen am 18.11.2026. Verfasst von José Luis Patier-de la Peña. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterised by abnormal angiogenesis caused by dysregulation of the BMP9/10–ALK1–ENG–SMAD signalling axis. The principal clinical manifestations are recurrent epistaxis, iron-deficiency anaemia, gastrointestinal bleeding and visceral arteriovenous malformations. Improved understanding of the molecular mechanisms underlying endothelial dysfunction has enabled the development of targeted therapeutic approaches that modulate angiogenic pathways involved in disease progression.
Methods
A narrative review was undertaken from clinical and translational perspectives. PubMed/MEDLINE, Scopus, Web of Science and ClinicalTrials.gov were searched for records published from January 2012 to May 2026. Medical Subject Headings (MeSH) and free-text terms related to HHT, angiogenesis, VEGF, FGFR, PI3K/AKT/mTOR, ANGPT2 and established or emerging therapies were used. Priority was accorded to randomised clinical trials, prospective studies, observational cohorts, systematic reviews, meta-analyses, international guidelines and consensus statements.
Results
Bevacizumab remains the systemic anti-VEGF therapy with the strongest clinical evidence in severe bleeding, transfusion-dependent anaemia and symptomatic hepatic vascular involvement. Pomalidomide is supported by the most robust randomised evidence for reducing moderate-to-severe epistaxis and improving quality of life. Multikinase inhibitors, including nintedanib and pazopanib, together with tacrolimus, sirolimus and beta-blockers, have broadened the range of therapeutic options, although several approaches require further validation. Most recently, the AKT inhibitor engasertib achieved clinically meaningful reductions in epistaxis frequency and duration, thereby providing the first direct clinical validation of AKT as a therapeutic target in HHT. Emerging strategies directed at ANGPT2/Tie2 and other vascular-stabilisation pathways may further expand future treatment options.
Conclusions
HHT management is progressively shifting towards a precision-medicine model that integrates genotype, haemorrhagic phenotype, visceral involvement, angiogenic biomarkers and treatment tolerability. Bevacizumab and pomalidomide are currently the best-established systemic therapies, whereas AKT inhibition is among the most promising recent developments. Further progress will require international collaboration, standardised outcome measures, biomarker-guided patient selection and prospectively validated and individualised treatment strategies.
Zitieren
APA
Peña, J. L. P. L. (2026). Abnormal Angiogenesis in Hereditary Haemorrhagic Telangiectasia: VEGF-, FGFR- and PI3K/AKT/mTOR-Targeted Therapies and IMiDs—A Narrative Review. Rare Diseases and Therapeutics, 1(1), 2. https://doi.org/10.3390/rdt1010002
Vancouver
Peña JLPL. Abnormal Angiogenesis in Hereditary Haemorrhagic Telangiectasia: VEGF-, FGFR- and PI3K/AKT/mTOR-Targeted Therapies and IMiDs—A Narrative Review. Rare Diseases and Therapeutics. 2026;1(1):2. doi:10.3390/rdt1010002
BibTeX
@article{Pea2026,
author = {Peña, José Luis Patier-de la},
title = {Abnormal Angiogenesis in Hereditary Haemorrhagic Telangiectasia: VEGF-, FGFR- and PI3K/AKT/mTOR-Targeted Therapies and IMiDs—A Narrative Review},
journal = {Rare Diseases and Therapeutics},
year = {2026},
volume = {1},
number = {1},
pages = {2},
doi = {10.3390/rdt1010002}
}
EUVIMED